Korro, FDA and Orphan Drug
KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...
Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).
Korro Bio, Inc. CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of ...
CAMBRIDGE, Mass. – Korro Bio, Inc. (NASDAQ:KRRO), a clinical-stage biopharmaceutical company with a market capitalization of $231 million, has received orphan drug designation from the U.S. Food ...
Explore Korro Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KRRO. U.S. stocks reacted positively following the Federal Open Market Committee's ...
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback